Ultragenyx Pharmaceutical (RARE) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$418.2 million.
- Ultragenyx Pharmaceutical's Enterprise Value rose 3194.88% to -$418.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$418.2 million, marking a year-over-year increase of 3194.88%. This contributed to the annual value of -$603.0 million for FY2024, which is 447.26% down from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its Enterprise Value stood at -$418.2 million for Q3 2025, which was up 3194.88% from -$480.6 million recorded in Q2 2025.
- In the past 5 years, Ultragenyx Pharmaceutical's Enterprise Value registered a high of -$412.1 million during Q1 2024, and its lowest value of -$965.4 million during Q1 2021.
- Its 5-year average for Enterprise Value is -$634.0 million, with a median of -$603.0 million in 2024.
- In the last 5 years, Ultragenyx Pharmaceutical's Enterprise Value crashed by 4555.1% in 2021 and then soared by 5025.25% in 2023.
- Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Enterprise Value stood at -$740.2 million in 2021, then decreased by 1.02% to -$747.8 million in 2022, then grew by 22.81% to -$577.2 million in 2023, then decreased by 4.47% to -$603.0 million in 2024, then surged by 30.64% to -$418.2 million in 2025.
- Its last three reported values are -$418.2 million in Q3 2025, -$480.6 million for Q2 2025, and -$487.4 million during Q1 2025.